while the 36-month beta value is 1.07.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Inovio Pharmaceuticals Inc. (INO) is $1.40, which is $0.52 above the current market price. The public float for INO is 245.68M, and currently, short sellers hold a 14.17% ratio of that floaft. The average trading volume of INO on April 20, 2023 was 5.34M shares.
INO) stock’s latest price update
Inovio Pharmaceuticals Inc. (NASDAQ: INO)’s stock price has increased by 0.02 compared to its previous closing price of 0.88. However, the company has seen a 19.92% increase in its stock price over the last five trading sessions.
INO’s Market Performance
Inovio Pharmaceuticals Inc. (INO) has experienced a 19.92% rise in stock performance for the past week, with a -17.62% drop in the past month, and a -50.20% drop in the past quarter. The volatility ratio for the week is 13.94%, and the volatility levels for the past 30 days are at 9.53% for INO. The simple moving average for the last 20 days is 4.07% for INO stock, with a simple moving average of -49.97% for the last 200 days.
Analysts’ Opinion of INO
BofA Securities, on the other hand, stated in their research note that they expect to see INO reach a price target of $2. The rating they have provided for INO stocks is “Underperform” according to the report published on November 01st, 2022.
RBC Capital Mkts gave a rating of “Sector Perform” to INO, setting the target price at $4 in the report published on July 19th of the previous year.
INO Trading at -23.46% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.66% of loss for the given period.
Volatility was left at 9.53%, however, over the last 30 days, the volatility rate increased by 13.94%, as shares sank -15.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.09% lower at present.
During the last 5 trading sessions, INO rose by +19.92%, which changed the moving average for the period of 200-days by -53.36% in comparison to the 20-day moving average, which settled at $0.8391. In addition, Inovio Pharmaceuticals Inc. saw -43.49% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at INO starting from Weiner David B., who sale 5,833 shares at the price of $1.15 back on Mar 13. After this action, Weiner David B. now owns 910,124 shares of Inovio Pharmaceuticals Inc., valued at $6,708 using the latest closing price.
Weiner David B., the Director of Inovio Pharmaceuticals Inc., sale 11,668 shares at $1.28 during a trade that took place back on Feb 27, which means that Weiner David B. is holding 904,291 shares at $14,935 based on the most recent closing price.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -2672.64 for the present operating margin
- +46.44 for the gross margin
The net margin for Inovio Pharmaceuticals Inc. stands at -2726.67. The total capital return value is set at -79.83, while invested capital returns managed to touch -82.09. Equity return is now at value -98.00, with -68.00 for asset returns.
Based on Inovio Pharmaceuticals Inc. (INO), the company’s capital structure generated 14.42 points at debt to equity in total, while total debt to capital is 12.61. Total debt to assets is 9.14, with long-term debt to equity ratio resting at 13.16. Finally, the long-term debt to capital ratio is 11.50.
When we switch over and look at the enterprise to sales, we see a ratio of 0.81, with the company’s debt to enterprise value settled at 0.21. The receivables turnover for the company is 1.04 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.25.
In a nutshell, Inovio Pharmaceuticals Inc. (INO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.